Search The Medical Knowledge Base

Drug Details

GAVISCON ADVANCE MINT CHEWABLE

• Generic Name
  sodium alginate
• Presentation
  Chewable tablet. An off-white to cream, circular, flat with bevelled edges tablet with the odour and flavour of peppermint. Each tablet is imprinted with a "Sword and Circle" on one side and "GA500" on the reverse.
• Description
  Each tablet contains sodium alginate 500 mg and potassium bicarbonate 100 mg
• Indications
  Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. It can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
• Adult Dosage
  

  For oral administration, after being thoroughly chewed.

  Adults and children 12 years and over: One to two tablets after meals and at bedtime.

  Children under 12 years: Should be given only on medical advice.

  Elderly: No dose modifications necessary for this age group.

• Contra Indications
  

  This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.

  This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients

• Special Precautions
  

  The sodium content of a two-tablet dose is 103 mg (4.5 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Due to its aspartame content this product should not be given to patients with phenylketonuria. May cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.

   

  The sodium content of a two-tablet dose is 103 mg (4.5 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels.

  Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

  Due to its aspartame content this product should not be given to patients with phenylketonuria.

  May cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure. There is a possibility of reduced efficacy in patients with very low levels of gastric acid.

  If symptoms do not improve after seven days, the clinical situation should be reviewed.

  Treatment of children younger than 12 years of age is not generally recommended, except on medical advice

• Interactions
  

  None known.

• Adverse Drug Reactions
  

  Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions